Innate Pharma S.A. – NASDAQ:IPHA

Innate Pharma S.A. stock price today

$2.29
+0.18
+8.53%
Financial Health
0
1
2
3
4
5
6
7
8
9

Innate Pharma S.A. stock price monthly change

-5.38%
month

Innate Pharma S.A. stock price quarterly change

-5.38%
quarter

Innate Pharma S.A. stock price yearly change

-22.71%
year

Innate Pharma S.A. key metrics

Market Cap
166.54M
Enterprise value
162.76M
P/E
-36.56
EV/Sales
8.85
EV/EBITDA
-85.93
Price/Sales
10.28
Price/Book
1.75
PEG ratio
N/A
EPS
-0.13
Revenue
82.72M
EBITDA
-21.10M
Income
-11.35M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-28.12%
Oper. margin
-22.72%
Gross margin
14.28%
EBIT margin
-22.72%
EBITDA margin
-25.51%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Innate Pharma S.A. stock price history

Innate Pharma S.A. stock forecast

Innate Pharma S.A. financial statements

Innate Pharma S.A. (NASDAQ:IPHA): Profit margin
Mar 2023 20.09M 859K 4.27%
Jun 2023 35.34M 1.71M 4.86%
Sep 2023 10.72M -4.64M -43.31%
Dec 2023 16.55M -9.28M -56.1%
Innate Pharma S.A. (NASDAQ:IPHA): Analyst Estimates
2025 96.85M 20.85M 21.53%
2026 123.51M 22.80M 18.47%
2027 68.07M -19.89M -29.23%
2028 138.18M 28.64M 20.73%
  • Analysts Price target

  • Financials & Ratios estimates

Innate Pharma S.A. (NASDAQ:IPHA): Debt to assets
Apr 2023 199049000 141.18M 70.93%
Jun 2023 199049000 141.18M 70.93%
Sep 2023 184193000 132.29M 71.82%
Dec 2023 184193000 132.29M 71.82%
Innate Pharma S.A. (NASDAQ:IPHA): Cash Flow
Mar 2023 -5.73M -123K -623K
Jun 2023 -11.46M -246K -1.24M
Sep 2023 -10.54M 10.43M -360K
Dec 2023 -21.09M 20.87M -720K

Innate Pharma S.A. alternative data

Innate Pharma S.A. (NASDAQ:IPHA): Employee count
Aug 2023 211
Sep 2023 211
Oct 2023 191
Nov 2023 191
Dec 2023 191
Jan 2024 191
Feb 2024 191
Mar 2024 191
Apr 2024 191
May 2024 179
Jun 2024 179
Jul 2024 179

Innate Pharma S.A. other data

0.34% -0.16%
of IPHA is owned by hedge funds
272.51K -127.24K
shares is hold by hedge funds
Insider Compensation
Dr. Mondher Mahjoubi M.D. (1958) Chairman of Executive Board & Chief Executive Officer
$747,830
Mr. Yannis Morel (1973) Executive Vice President of Product Portfolio Strategy & Bus. Devel. and Member of Executive Board
$345,050
Ms. Laure-Helene Mercier M.B.A., M.Sc., MSc, MBA (1978) Executive Vice President of Fin. & Corporation Strategy
$288,940
Friday, 20 December 2024
businesswire.com
Monday, 9 December 2024
businesswire.com
Friday, 6 December 2024
businesswire.com
Tuesday, 3 December 2024
businesswire.com
Monday, 25 November 2024
seekingalpha.com
Wednesday, 20 November 2024
businesswire.com
Tuesday, 19 November 2024
businesswire.com
Wednesday, 13 November 2024
seekingalpha.com
businesswire.com
Friday, 8 November 2024
businesswire.com
Thursday, 7 November 2024
businesswire.com
Tuesday, 29 October 2024
businesswire.com
Monday, 14 October 2024
businesswire.com
Monday, 30 September 2024
businesswire.com
Monday, 23 September 2024
businesswire.com
Thursday, 12 September 2024
seekingalpha.com
businesswire.com
Thursday, 5 September 2024
businesswire.com
Wednesday, 4 September 2024
businesswire.com
Thursday, 1 August 2024
businesswire.com
Monday, 17 June 2024
businesswire.com
Tuesday, 4 June 2024
businesswire.com
Tuesday, 28 May 2024
businesswire.com
Friday, 24 May 2024
businesswire.com
Thursday, 23 May 2024
businesswire.com
Tuesday, 21 May 2024
businesswire.com
Wednesday, 15 May 2024
businesswire.com
Tuesday, 14 May 2024
seekingalpha.com
businesswire.com
Tuesday, 7 May 2024
Business Wire
  • What's the price of Innate Pharma S.A. stock today?

    One share of Innate Pharma S.A. stock can currently be purchased for approximately $2.29.

  • When is Innate Pharma S.A.'s next earnings date?

    Unfortunately, Innate Pharma S.A.'s (IPHA) next earnings date is currently unknown.

  • Does Innate Pharma S.A. pay dividends?

    No, Innate Pharma S.A. does not pay dividends.

  • How much money does Innate Pharma S.A. make?

    Innate Pharma S.A. has a market capitalization of 166.54M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 4.56% to 51.9M US dollars.

  • What is Innate Pharma S.A.'s stock symbol?

    Innate Pharma S.A. is traded on the NASDAQ under the ticker symbol "IPHA".

  • What is Innate Pharma S.A.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Innate Pharma S.A.?

    Shares of Innate Pharma S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Innate Pharma S.A.'s key executives?

    Innate Pharma S.A.'s management team includes the following people:

    • Dr. Mondher Mahjoubi M.D. Chairman of Executive Board & Chief Executive Officer(age: 67, pay: $747,830)
    • Mr. Yannis Morel Executive Vice President of Product Portfolio Strategy & Bus. Devel. and Member of Executive Board(age: 52, pay: $345,050)
    • Ms. Laure-Helene Mercier M.B.A., M.Sc., MSc, MBA Executive Vice President of Fin. & Corporation Strategy(age: 47, pay: $288,940)
  • How many employees does Innate Pharma S.A. have?

    As Jul 2024, Innate Pharma S.A. employs 179 workers, which is 6% less then previous quarter.

  • When Innate Pharma S.A. went public?

    Innate Pharma S.A. is publicly traded company for more then 5 years since IPO on 17 Oct 2019.

  • What is Innate Pharma S.A.'s official website?

    The official website for Innate Pharma S.A. is innate-pharma.com.

  • How can i contact Innate Pharma S.A.?

    Innate Pharma S.A. can be reached via phone at +33 4 30 30 30 30.

Innate Pharma S.A. company profile:

Innate Pharma S.A.

innate-pharma.com
Exchange:

NASDAQ

Full time employees:

168

Industry:

Biotechnology

Sector:

Healthcare

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.

117, Avenue de Luminy
Marseille, 13009

CIK: 0001598599
ISIN: US45781K2042
CUSIP: 45781K204